Daniil Gataulin
Stock Analyst at Chardan Capital
(3.92)
# 1,830
Out of 4,534 analysts
75
Total ratings
38.8%
Success rate
13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniil Gataulin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCUL Ocular Therapeutix | Maintained: Buy | $21 → $23 | $8.97 | +156.41% | 3 | Jun 25, 2026 | |
| IRD Opus Genetics | Maintained: Buy | $11 → $13 | $3.27 | +297.55% | 3 | Jun 17, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $21 | $3.08 | +581.82% | 7 | May 17, 2026 | |
| MGTX MeiraGTx Holdings | Reiterated: Buy | $36 → $35 | $12.44 | +181.35% | 2 | May 14, 2026 | |
| OCS Oculis Holding AG | Reiterated: Buy | $51 → $53 | $12.19 | +334.78% | 3 | May 12, 2026 | |
| FBRX Forte Biosciences | Reiterated: Buy | $61 | $48.86 | +24.85% | 3 | May 11, 2026 | |
| KOD Kodiak Sciences | Upgraded: Buy | $14 → $61 | $42.64 | +43.06% | 6 | May 11, 2026 | |
| CGTX Cognition Therapeutics | Reiterated: Buy | $8 → $4 | $0.9608 | +316.32% | 3 | May 8, 2026 | |
| OCGN Ocugen | Reiterated: Buy | $5 → $7 | $1.36 | +414.71% | 8 | May 7, 2026 | |
| ZURA Zura Bio | Reiterated: Buy | $10 → $11 | $5.45 | +101.83% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 | $13.30 | +118.05% | 6 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $40.25 | -8.07% | 8 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 | $9.89 | +425.78% | 8 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $1 | $1.39 | -28.06% | 6 | Jan 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $16 | $5.80 | +175.86% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $4.38 | +333.79% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.0822 | n/a | 1 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $12.25 | n/a | 2 | Feb 15, 2023 |
Ocular Therapeutix
Jun 25, 2026
Maintained: Buy
Price Target: $21 → $23
Current: $8.97
Upside: +156.41%
Opus Genetics
Jun 17, 2026
Maintained: Buy
Price Target: $11 → $13
Current: $3.27
Upside: +297.55%
CervoMed
May 17, 2026
Reiterated: Buy
Price Target: $21
Current: $3.08
Upside: +581.82%
MeiraGTx Holdings
May 14, 2026
Reiterated: Buy
Price Target: $36 → $35
Current: $12.44
Upside: +181.35%
Oculis Holding AG
May 12, 2026
Reiterated: Buy
Price Target: $51 → $53
Current: $12.19
Upside: +334.78%
Forte Biosciences
May 11, 2026
Reiterated: Buy
Price Target: $61
Current: $48.86
Upside: +24.85%
Kodiak Sciences
May 11, 2026
Upgraded: Buy
Price Target: $14 → $61
Current: $42.64
Upside: +43.06%
Cognition Therapeutics
May 8, 2026
Reiterated: Buy
Price Target: $8 → $4
Current: $0.9608
Upside: +316.32%
Ocugen
May 7, 2026
Reiterated: Buy
Price Target: $5 → $7
Current: $1.36
Upside: +414.71%
Zura Bio
May 7, 2026
Reiterated: Buy
Price Target: $10 → $11
Current: $5.45
Upside: +101.83%
May 6, 2026
Reiterated: Buy
Price Target: $29
Current: $13.30
Upside: +118.05%
May 5, 2026
Reiterated: Buy
Price Target: $37
Current: $40.25
Upside: -8.07%
Jan 28, 2026
Reiterated: Buy
Price Target: $52
Current: $9.89
Upside: +425.78%
Jan 2, 2026
Maintained: Hold
Price Target: $3 → $1
Current: $1.39
Upside: -28.06%
Dec 23, 2025
Initiated Coverage: Buy
Price Target: $16
Current: $5.80
Upside: +175.86%
Dec 23, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $4.38
Upside: +333.79%
Jun 13, 2025
Maintained: Hold
Price Target: n/a
Current: $0.0822
Upside: n/a
Feb 15, 2023
Downgraded: Hold
Price Target: n/a
Current: $12.25
Upside: n/a